Last update May 19, 2021
Very Low Risk
Second generation anti-histaminic and piperidine drug with a slightly sedative effect.
It is indicated in the symptomatic treatment of allergic rhinitis and pruritic skin disorders.
Oral administration once daily.
It is excreted in breast milk in clinically insignificant amounts and no problems have been observed in infants whose mothers have taken it . Plasma levels in these infants were very low (Saito 2020).
Its high percentage of plasma protein binding and very high volume of distribution (Cuvillo 2006) explain the negligible passage into milk observed.
Second generation anti-histaminic medicines are considered to be safe while breastfeeding (So 2010, Leimgruber 2007, Solhaug 2004).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM